114 related articles for article (PubMed ID: 36882345)
21. Comparison of 2D vs. 3D dosimetry for Rotte 'Y' applicator high dose rate brachytherapy for medically inoperable endometrial cancer.
Beriwal S; Kim H; Heron DE; Selvaraj R
Technol Cancer Res Treat; 2006 Oct; 5(5):521-7. PubMed ID: 16981795
[TBL] [Abstract][Full Text] [Related]
22. A dosimetric comparison of Volumetric Modulated Arc Therapy (VMAT) and High Dose Rate (HDR) brachytherapy in localized cervical cancer radiotherapy.
Wali L; Helal A; Darwesh R; Attar M
J Xray Sci Technol; 2019; 27(3):473-483. PubMed ID: 30958322
[TBL] [Abstract][Full Text] [Related]
23. Variable impact of intracavitary brachytherapy fractionation schedule on biologically effective dose to organs at risk in patients with cervical cancer.
Christensen EN; Yu HZ; Klopp AH; Tsai JC; Lawyer AA; Court LE; Eifel PJ
Brachytherapy; 2014; 13(3):240-9. PubMed ID: 24188993
[TBL] [Abstract][Full Text] [Related]
24. A novel two-step optimization method for tandem and ovoid high-dose-rate brachytherapy treatment for locally advanced cervical cancer.
Sharma M; Fields EC; Todor DA
Brachytherapy; 2015; 14(5):613-8. PubMed ID: 26092424
[TBL] [Abstract][Full Text] [Related]
25. Dose-volume histogram analysis of composite EQD2 dose distributions using the central shielding technique in cervical cancer radiotherapy.
Tamaki T; Noda SE; Ohno T; Kumazaki Y; Kato S; Nakano T
Brachytherapy; 2016; 15(5):598-606. PubMed ID: 27475482
[TBL] [Abstract][Full Text] [Related]
26. Comparison between CT-based volumetric calculations and ICRU reference-point estimates of radiation doses delivered to bladder and rectum during intracavitary radiotherapy for cervical cancer.
Pelloski CE; Palmer M; Chronowski GM; Jhingran A; Horton J; Eifel PJ
Int J Radiat Oncol Biol Phys; 2005 May; 62(1):131-7. PubMed ID: 15850913
[TBL] [Abstract][Full Text] [Related]
27. Early outcomes and impact of a hybrid IC/IS applicator for a new MRI-based cervical brachytherapy program.
Harkenrider MM; Surucu M; Harmon G; Mysz ML; Shea SM; Yacoub J; Goldberg A; Liotta M; Winder A; Potkul R; Roeske JC; Small W
Brachytherapy; 2018; 17(1):187-193. PubMed ID: 29089277
[TBL] [Abstract][Full Text] [Related]
28. Single versus customized treatment planning for image-guided high-dose-rate brachytherapy for cervical cancer: dosimetric comparison and predicting factor for organs at risk overdose with single plan approach.
Chi A; Gao M; Sinacore J; Nguyen NP; Vali F; Albuquerque K
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):309-14. PubMed ID: 19540070
[TBL] [Abstract][Full Text] [Related]
29. A comparison of ICRU point doses and volumetric doses of organs at risk (OARs) in brachytherapy for cervical cancer.
Vinod SK; Caldwell K; Lau A; Fowler AR
J Med Imaging Radiat Oncol; 2011 Jun; 55(3):304-10. PubMed ID: 21696566
[TBL] [Abstract][Full Text] [Related]
30. A comparison of organs at risk doses in GYN intracavitary brachytherapy for different tandem lengths and bladder volumes.
Siavashpour Z; Aghamiri MR; Jaberi R; ZareAkha N; Manshadi HRD; Kirisits C; Sedaghat M
J Appl Clin Med Phys; 2016 May; 17(3):5-13. PubMed ID: 27167253
[TBL] [Abstract][Full Text] [Related]
31. Point vs. volumetric bladder and rectal doses in combined intracavitary-interstitial high-dose-rate brachytherapy: correlation and comparison with published Vienna applicator data.
Yaparpalvi R; Mutyala S; Gorla GR; Butler J; Mah D; Garg MK; Kalnicki S
Brachytherapy; 2008; 7(4):336-42. PubMed ID: 18782683
[TBL] [Abstract][Full Text] [Related]
32. Implications of applicators orientations on bladder, and rectal doses in gynecological mHDR brachytherapy: A retrospective analysis of reproducibility in multi-fractionated regimen.
Srivastava AK; Rastogi M; Mishra SP
J Cancer Res Ther; 2019; 15(6):1345-1351. PubMed ID: 31898671
[TBL] [Abstract][Full Text] [Related]
33. Feasibility study of toxicity outcomes using GEC-ESTRO contouring guidelines on CT based instead of MRI-based planning in locally advanced cervical cancer patients.
Koh V; Choo BA; Lee KM; Tan TH; Low JH; Ng SY; Ilancheran A; Shen L; Tang J
Brachytherapy; 2017; 16(1):126-132. PubMed ID: 27816539
[TBL] [Abstract][Full Text] [Related]
34. Dose and volume parameters for MRI-based treatment planning in intracavitary brachytherapy for cervical cancer.
Kirisits C; Pötter R; Lang S; Dimopoulos J; Wachter-Gerstner N; Georg D
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):901-11. PubMed ID: 15936576
[TBL] [Abstract][Full Text] [Related]
35. Preliminary results of conformal computed tomography (CT)-based intracavitary brachytherapy (ICBT) for locally advanced cervical cancer: a single institution's experience.
Tharavichitkul E; Mayurasakorn S; Lorvidhaya V; Sukthomya V; Wanwilairat S; Lookaew S; Pukanhaphan N; Chitapanarux I; Galalae R
J Radiat Res; 2011; 52(5):634-40. PubMed ID: 21952319
[TBL] [Abstract][Full Text] [Related]
36. A comprehensive evaluation of adaptive daily planning for cervical cancer HDR brachytherapy.
Meerschaert R; Nalichowski A; Burmeister J; Paul A; Miller S; Hu Z; Zhuang L
J Appl Clin Med Phys; 2016 Nov; 17(6):323-333. PubMed ID: 27929505
[TBL] [Abstract][Full Text] [Related]
37. Three-dimension anatomy-based planning optimization for high dose rate vaginal vault brachytherapy.
Bahadur YA; Hassouna AH; Constantinescu CT; Naga AF; Ghasal NM; Elsayed ME
Saudi Med J; 2012 Jun; 33(6):640-7. PubMed ID: 22729119
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of dose differences between intracavitary applicators for cervical brachytherapy using knowledge-based models.
Kallis K; Mayadev J; Covele B; Brown D; Scanderbeg D; Simon A; Frisbie-Firsching H; Yashar CM; Einck JP; Mell LK; Moore KL; Meyers SM
Brachytherapy; 2021; 20(6):1323-1333. PubMed ID: 34607771
[TBL] [Abstract][Full Text] [Related]
39. Impact of delineation uncertainties on dose to organs at risk in CT-guided intracavitary brachytherapy.
Duane FK; Langan B; Gillham C; Walsh L; Rangaswamy G; Lyons C; Dunne M; Walker C; McArdle O
Brachytherapy; 2014; 13(2):210-8. PubMed ID: 24090973
[TBL] [Abstract][Full Text] [Related]
40. Early outcomes of abbreviated multi-fractionated brachytherapy schedule for cervix cancer during COVID-19 pandemic.
Chopra S; Mulani J; Mittal P; Singh M; Shinde A; Gurram L; Scaria L; Aravindakshan D; Kohle S; Rane P; Ghadi Y; Rath S; Ghosh J; Gulia S; Gupta S; Kinhikar R; Laskar S; Agarwal JP
Brachytherapy; 2023; 22(2):125-131. PubMed ID: 36585283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
